Compare DSWL & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSWL | ESLA |
|---|---|---|
| Founded | 1987 | 2021 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 48.9M |
| IPO Year | 1995 | N/A |
| Metric | DSWL | ESLA |
|---|---|---|
| Price | $3.35 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 13.4K | ★ 81.5K |
| Earning Date | 11-13-2025 | 02-26-2026 |
| Dividend Yield | ★ 6.08% | N/A |
| EPS Growth | ★ 20.23 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $65,664,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.93 | $0.73 |
| 52 Week High | $4.48 | $3.15 |
| Indicator | DSWL | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 39.14 |
| Support Level | $3.00 | $0.90 |
| Resistance Level | $3.43 | $1.13 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 72.92 | 22.79 |
Deswell Industries Inc is engaged in the manufacturing and selling of injection-molded plastic parts and components. In addition, it also offers manufacturing services for electronic products and subassemblies and manufactures metallic molds and accessory parts for original equipment manufacturers and contract manufacturers. The company conducts all of its manufacturing activities at separate plastics, electronics and metallic operation factories located in the People's Republic of China. It operates through the Plastic Injection Molding and Electronic Products Assembling segments. The firm offers products such as automobile components, medical testing equipment, parts for audio equipment, av receivers, active subwoofers, digital system key sets, communication products and others.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.